Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

June 3, 2011 updated by: Ichor Medical Systems Incorporated

A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma

The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence. In this study, the vaccine will be administered intramuscularly using a device that applies brief electrical fields to the tissue at the site of injection (a technique known as electroporation). It is expected that this device will improve the delivery of the vaccine. This study is being performed to determine if this procedure can be administered safely and if it is capable of inducing immune responses to the vaccine.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study is designed to evaluate administration of a xenogeneic DNA vaccine encoding the melanosomal antigen tyrosinase by in vivo electroporation in patients with malignant melanoma. The objectives of the study are to characterize the safety and immunogenicity of a DNA vaccine encoding the murine tyrosinase gene delivered administered intramuscularly using the electroporation based TriGrid Delivery System (Ichor Medical Systems). We will assess the nature, frequency, and severity of any toxicity associated with vaccination at escalating pINGmuTyr doses and then expand enrollment at then expand enrollment at the Maximum Tolerated Dose to assess immunologic responses to the tyrosinase antigen.

The hypotheses being tested are that the procedure is feasible and safe and that it induces immune responses specific for tyrosinase in patients with stage IIB-IV malignant melanoma.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10021
        • Memorial Sloan Kettering Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients must have documented, histologically confirmed malignant melanoma, American Joint Commission on Cancer (AJCC) Stage IIB- IV. Patients with stage IIb-III disease are only eligible after standard surgical care with wide local excision and appropriate lymph node sampling. Patients with stage IIb, IIc, or III melanoma who are free of disease after surgical resection are also eligible, only if they have refused high dose Interferon-alfa (INTRON A) or have had a recurrence while on Interferon-alfa.
  • Patients with choroidal melanoma may participate if they fulfill one of the following criteria: Basal diameter >16mm; Height >8mm or involvement of the ciliary body with tumor.
  • Patients must be at least 18 years of age and must be capable of understanding the consent form and giving informed consent.
  • Karnofsky Score > 80
  • Life Expectancy > 6 months
  • HLA-A1, A2, A24, or B35+ as assessed by low resolution phenotyping
  • White blood cell count ≥ 2,000/mm3
  • Platelet count ≥ 100,000/mm3
  • Neutrophil count ≥ 1,000/mm3
  • Hemoglobin ≥ 9.0 g/dL
  • Serum AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Serum Bilirubin ≤ 2.0 mg/dL
  • Serum Creatinine ≤ 2.0 mg/dL
  • Serum Alkaline Phosphatase < 2.5 times ULN
  • Serum Creatine phosphokinase (CPK) < 2.5 times ULN

Exclusion Criteria:

  • Documented metastases in brain
  • Clinical history of HIV, HepB, HepC, and/or HTLV I.
  • Active autoimmune disease other than vitiligo
  • Patients previously immunized using the tyrosinase DNA sequence, protein, or peptides.
  • Systemic immunosuppressive therapy (corticosteroids, or other immunosuppressive drugs) within the previous 28 days
  • Surgery and/or radiotherapy within the previous 28 days
  • Chemotherapy and/or biotherapy within the previous 28 days
  • Participation in an investigational study within previous 28 days
  • Patients with cardiac demand pacemakers.
  • Women who are pregnant or < 3 months post partum or nursing.
  • Women of child-bearing potential and sexually active men must be using appropriate contraception during the course of this study.
  • Any other concurrent medical condition that in the opinion of the Principal Investigator or co-Principal Investigator's would preclude study compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Xenogeneic Tyrosinase
Biological: Xenogeneic Tyrosinase DNA Vaccine
Device: TriGrid Delivery System for Intramuscular Electroporation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Evaluate the safety and feasibility of electroporation mediated intramuscular delivery of a mouse tyrosinase plasmid DNA vaccine in patients with stage IIB, IIC, III, or IV melanoma.
Time Frame: one year
one year

Secondary Outcome Measures

Outcome Measure
Time Frame
Assess patients with measurable tumor for evidence of anti-tumor response following immunization.
Time Frame: 6 months
6 months
Assess the magnitude and frequency of tyrosinase specific immunologic responses in the immunized patients
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ichor Medical Systems Incorporated

Collaborators

Memorial Sloan Kettering Cancer Center

Investigators

  • Principal Investigator: Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2007

Primary Completion (Actual)

May 1, 2010

Study Completion (Actual)

May 1, 2010

Study Registration Dates

First Submitted

May 8, 2007

First Submitted That Met QC Criteria

May 8, 2007

First Posted (Estimate)

May 9, 2007

Study Record Updates

Last Update Posted (Estimate)

June 7, 2011

Last Update Submitted That Met QC Criteria

June 3, 2011

Last Verified

June 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 07-003

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intraocular Melanoma

Clinical Trials on Xenogeneic Tyrosinase DNA Vaccine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe